Business Description
Entero Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US05502L1052
Description
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address significant unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 2.31 | |||||
| Equity-to-Asset | 0.82 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Piotroski F-Score | 3/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 87.9 | |||||
| 3-Year EPS without NRI Growth Rate | 74.9 | |||||
| 3-Year FCF Growth Rate | 84.9 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 60.63 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 50.68 | |||||
| 9-Day RSI | 43.2 | |||||
| 14-Day RSI | 44.27 | |||||
| 6-1 Month Momentum % | -76.65 | |||||
| 12-1 Month Momentum % | -87.5 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 5.34 | |||||
| Quick Ratio | 5.34 | |||||
| Cash Ratio | 0.02 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1182.5 | |||||
| Shareholder Yield % | -725.98 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -21.99 | |||||
| ROA % | -17.97 | |||||
| ROIC % | -16.08 | |||||
| ROC (Joel Greenblatt) % | -67.82 | |||||
| ROCE % | -39.97 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.27 | |||||
| Price-to-Tangible-Book | 0.34 | |||||
| EV-to-EBIT | -3.42 | |||||
| EV-to-EBITDA | -3.43 | |||||
| EV-to-Forward-Revenue | -64.47 | |||||
| EV-to-FCF | -5.1 | |||||
| Price-to-Net-Current-Asset-Value | 0.35 | |||||
| Earnings Yield (Greenblatt) % | -29.24 | |||||
| FCF Yield % | -554.64 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ENTO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Entero Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -6.747 | ||
| Beta | 0.98 | ||
| Volatility % | 150.33 | ||
| 14-Day RSI | 44.27 | ||
| 14-Day ATR ($) | 0.073257 | ||
| 20-Day SMA ($) | 0.54915 | ||
| 12-1 Month Momentum % | -87.5 | ||
| 52-Week Range ($) | 0.185 - 14.51 | ||
| Shares Outstanding (Mil) | 4.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Entero Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Entero Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Entero Therapeutics Inc Frequently Asked Questions
What is Entero Therapeutics Inc(ENTO)'s stock price today?
The current price of ENTO is $0.47. The 52 week high of ENTO is $14.51 and 52 week low is $0.19.
When is next earnings date of Entero Therapeutics Inc(ENTO)?
The next earnings date of Entero Therapeutics Inc(ENTO) is 2025-02-13 Est..
Does Entero Therapeutics Inc(ENTO) pay dividends? If so, how much?
Entero Therapeutics Inc(ENTO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers